Thereby, patients with IDH-mutated GBM may benefit from glutamine metabolism targeting, since it will efficiently disrupt de novo lipids synthesis, crucial to sustaining cancer cell proliferation and tumor growth [136]. The gene discussed is IDH2; the disease is cancer.